American Journal of Hypertension Advance Access published August 14, 2014
CliniCal Trial
Long-Term Effects of Continuous Positive Airway Pressure
on Blood Pressure and Prognosis in Hypertensive Patients
with Coronary Heart Disease and Obstructive Sleep Apnea:
A Randomized Controlled Trial
Zhiwei Huang,1 Zhihong Liu,1 Qin Luo,1 Qing Zhao,1 Zhihui Zhao,1 Xiuping Ma,1 Weihua Liu,1 and
Dan Yang1
background P = 0.02); however, DBP did not reach statistical difference between
Obstructive sleep apnea (OSA) can result in hypertension and signifi- the groups (81 ± 10 mm Hg vs. 79 ± 8 mm Hg; P = 0.49). In the CPAP
cantly increase cardiovascular morbidity and mortality. There are few group, the Epworth Sleepiness Scale was markedly reduced (7.0 ± 3.4
reports on the long-term effects of continuous positive airway pressure vs. 3.7 ± 2.3; P < 0.001). There was 1 SCCE in the CPAP group (heart
(CPAP) on blood pressure in patients with uncontrolled hypertension failure), and 5 SCCEs in the control group (acute myocardial infarc-
with coronary heart disease (CHD) and OSA. tion: 2 (with 1 death); stroke: 3), but there was no significant difference
identified.
methods
We conducted a prospective, long-term follow-up study in 83 patients conclusions
with uncontrolled hypertension, CHD, and OSA randomized to control Long-term CPAP application in uncontrolled hypertension with CHD
or CPAP groups. Daytime systolic blood pressure (SBP), diastolic blood and OSA significantly reduced daytime SBP, improved hypertension
pressure (DBP), and severe cardiovascular and cerebrovascular events control and daytime sleepiness, and decreased the trend in SCCEs com-
(SCCEs) were recorded at baseline and follow-up. pared with control subjects.
results clinical trial registration number:
Seventy-three patients completed the study with a median follow-up ClinicalTrials.gov NCT02059993.
of 36 (interquartile range = 24–54) months. The 2 groups had similar
characteristics at baseline. CPAP was used for 4.5 ± 1.1 hour/night. SBP Keywords: antihypertensive drugs; blood pressure; continuous posi-
in the CPAP group was significantly reduced at follow-up (143 ± 7 mm tive airway pressure; coronary heart disease; hypertension; obstructive
Hg vs. 139 ± 7 mm Hg, P = 0.04), and SBP decreased by 8 mm Hg (95% sleep apnea.
confidence interval = 1.4–9.9; P = 0.01). Hypertension control was
improved (CPAP, 69.4% for CPAP users vs. 43.2% for control subjects; doi:10.1093/ajh/hpu147
Obstructive sleep apnea (OSA) is a common disorder significantly increases cardiovascular morbidity and mor-
characterized by repetitive partial (hypopnea) or complete tality, especially in patients with preexisting cardiovascular
(apnea) occlusion of the upper airway during sleep, which disease.7 Several studies8–13 have found that continuous posi-
is caused by collapse of the pharyngeal airway and results tive airway pressure (CPAP) reduces systolic blood pressure
in sleep fragmentation and oxyhemoglobin desaturation.1 (SBP) and diastolic blood pressure (DBP) in patients with
A study by Kiely and colleagues has shown that >20% of OSA. Additionally, some articles have reported that there is
hypertensive patients exhibit OSA, whereas the prevalence of a protective effect of CPAP therapy against death from car-
hypertension in the setting of OSA is >50%.2 One study con- diovascular disease in patients with severe OSA.14,15 Other
firms that OSA is an important identifiable cause of hyper- studies have not demonstrated that CPAP has an antihy-
tension.3 OSA is considered as one of the most common risk pertensive effect.16,17 However, relevant studies have a rela-
factors of resistant hypertension.4,5 The estimated prevalence tive short study duration, with few extending longer than
of OSA among male patients with coronary artery disease 1 year. In our opinion, they are not sufficient to detect the
(CAD) is 37%.6 A previous study has suggested that OSA real effects of CPAP on blood pressure (BP). Based on our
Correspondence: Zhihong Liu (zhihongliufuwai@163.com). 1State Key Laboratory of Cardiovascular Disease, Fuwai Hospital,
National Center for Cardiovascular Diseases, Chinese Academy of
Initially submitted April 28, 2014; date of first revision May 26, 2014; Medical Sciences and Peking Union Medical College, Beijing, China.
accepted for publication June 30, 2014.
© American Journal of Hypertension, Ltd 2014. All rights reserved.
For Permissions, please email: journals.permissions@oup.com
American Journal of Hypertension 1
Downloaded
from
http://ajh.oxfordjournals.org/
at
University
of
California,
Santa
Cruz
on
February
11,
2015
Huang et al.
knowledge, there are few reports about long-term effects of (including corticosteroids or sedative drugs); currently used
CPAP, including whether CPAP application can improve CPAP treatment for OSA or pharyngeal surgery for OSA;
the prognosis of OSA patients with preexisting CHD under declined to participate; or were unable to give informed
conventional medications.18,19 Therefore, we conducted a consent.
long-term, prospective, controlled study to investigate the
effects of CPAP on BP, prognosis, clinical symptoms, and Study protocol
severe cardiovascular and cerebrovascular events (SCCEs)
in hypertensive patients with CHD and OSA on conven- At baseline, resting BP was measured; demographic data,
tional treatment. including age, sex, medical history, therapeutic regimen, life-
style habits, height (cm), weight (kg), waist circumference
(cm), hip circumference (cm), and neck circumference (cm),
METHODS
were recorded; and body mass index (BMI) was calculated as
Study design and setting weight divided by height squared (kg/m2). Patients assessed
their subjective daytime somnolence using the ESS,21 a self-
We performed a prospective, randomized, single-center completed questionnaire specific to symptoms of daytime
clinical trial of parallel groups in hypertensive patients with sleepiness in various daytime situations. Patients underwent
CHD and OSA. We used a computer program to produce regular clinical examination and laboratory tests to exclude
the randomized treatment number. These were stored in secondary hypertension. After the initial evaluation, physi-
sequentially numbered opaque envelopes. The project man- cian would give lifestyle advice (including smoking cessa-
ager was responsible for the allocation and had no contact tion and heavy drinking discontinuation). Participants were
with any of the participants throughout the trial. Patients assigned antihypertensive and CHD drugs treatments based
were randomly assigned to either CPAP or no therapy on current guidelines (defined as conventional medications)
(control). This study was approved by the ethics commit- in a 3-month run-in period that allowed for modifications
tee of Fuwai Hospital (No. 2009215). Informed consent was in therapeutic schedule. Patients enrolled in the study were
obtained from each patient. advised not to change their therapeutic regimen without
permission from their physicians. Drug change was defined
Patient selection as any adjustment of antihypertensive treatment. SCCEs
included new-onset acute myocardial infarction (AMI),
We recruited consecutive patients from outpatient and hospitalization for heart failure, need for repeated coronary
inpatient departments of Fuwai Hospital from January 2009 revascularization, stroke, and death associated with cardio-
to June 2012. Patients who were diagnosed with moderate to vascular and cerebrovascular disease.
severe OSA (moderate OSA was defined as an apnea–hypo- Patients visited the sleep research laboratory at 1 and
pnea index (AHI) of 15–29 episodes/hour, and severe OSA 3 months after randomization and every 6 months thereafter.
was defined as an AHI of at least 30 episodes/hour) docu- Follow-up ended on 31 December 2013, and was carried out
mented by polysomnography,20 hypertension (hypertension in all cases by the same investigator. Every medical appoint-
is defined as systolic pressure ≥140 mm Hg and/or diastolic ment involved protocol-based assessments of the following:
pressure ≥90 mm Hg at rest or treatment with antihyperten- morning office BP and heart rate after the patient rested for
sive medication) and confirmation of CHD (selective coro- 10 minutes, adherence to CPAP, medical treatment, lifestyle
nary angiograms showed at least 1 major epicardial coronary habits, height, weight, waist circumference, hip circum-
artery luminal stenosis segment ≥70%, or left main coronary ference, neck circumference, and ESS. Any SCCEs were
artery stenosis ≥50%, history of myocardial infarction, or recorded, and patients or their relatives were asked to pro-
coronary artery bypass grafting documented by medical vide relevant medical documents. The physicians that han-
record) were included in this study. The criteria for inclu- dled the medical treatment as well as the clinical assessment
sion were as follows: (i) men and women aged 45–75 years; and measured BP during the follow-up were blinded to the
(ii) verified diagnosis of hypertension by medical history CPAP status of the patients. Patients were asked to bring the
or treatment with antihypertensive medications; (iii) estab- empty blister packs of their pills to ensure compliance with
lished diagnosis of CHD; (iv) at least 3-month optimal the treatment. Hypertension control was defined as rest-
treatment for hypertension but BP still >140/90 mm Hg or ing BP <140/90 mm Hg or <130/80 mm Hg in patients with
>130/80 mm Hg in patients with diabetes; and (v) moder- diabetes.22
ate to severe OSA. The subjects were excluded if they had
secondary hypertension (including renal artery stenosis, BP measurement
chronic renal disease, and primary aldosteronism), central
sleep apnea (defined as at least 50% of respiratory events To avoid the white-coat effect, BP measurements at the
having a pattern of apnea or hypopnea without thoracic and time of follow-up were recorded in a home-like environ-
abdominal movement), an Epworth Sleepiness Scale (ESS) ment. The physician in charge of BP measurements received
score ≥15, a history of significant hepatic failure or severe training of BP measurements for 2 weeks before the trial.
pulmonary disease, malignant cancer with a life expectancy The morning BP was measured with a mercury sphyg-
of <2 years, severe psychiatric disease, sustained excessive momanometer by an experienced physician unaware of the
alcohol use, or New York Heart Association class III–IV patient’s group assignment. Patients were seated for at least
heart failure; regularly used medications that can affect BP 10 minutes in a quiet environment with feet on the floor
2 American Journal of Hypertension
Downloaded
from
http://ajh.oxfordjournals.org/
at
University
of
California,
Santa
Cruz
on
February
11,
2015
Effects of CPAP on Hypertensive Patients with OSA
and their arm supported at heart level. An appropriate sized after CPAP treatment, assuming an alpha error of 5% and a
cuff was placed on the arm with the lower edge of the cuff statistical power of 80%. For baseline comparison between
2 cm above the antecubital fossa. The first and last Korotkoff the control and CPAP groups, a 2-tailed test was used for
sounds were used to determine SBP and DBP, respectively. normally distributed variables, and a Mann–Whitney test
The average of 3 consecutive BP measurements with 2-min- for non-normally distributed variables. The intragroup
ute intervals on the same arm of the patient was recorded changes from baseline to the end of follow-up were assessed
for the study. with a paired t test and Wilcoxon signed rank test. The χ2 test
was used to compare categorical variables. Fisher’s exact test
was used when ≥1 cells contained values ≤5. SPSS version 18
Sleep evaluation
software (SPSS, Chicago, IL) was used for statistical analysis.
An overnight polysomnography was performed on all of P < 0.05 was considered statistically significant.
the included patients in the Sleep Center of Fuwai Hospital
by using the Embletta (Medcare Flaga, Reykjavik, Iceland) RESULTS
to record nasal airflow, finger pulse oximetry, thoracic and
abdominal movement, body position, and snoring. The sleep The study flow chart is depicted in Figure 1. A total of
was monitored automatically for 7 hours, starting from 30 243 patients were screened between January 2009 and June
minutes after the subjects went to bed. Polygraphy data were 2012. Out of 97 (39.9%) patients diagnosed with OSA, 5 sub-
scored manually by trained personnel. Polysomnography jects declined to participate in the study, and 9 subjects were
was repeated in both groups at the end of follow-up. Apnea excluded because of the following: AHI <15 (n = 8 patients)
was defined as airflow reduction to ≤10% of the baseline and severe heart failure (n = 1 patient). A total of 83 patients
value for 10 seconds or more. Hypopnea was defined as a fulfilled the inclusion criteria. Of these, 42 patients were
30%–90% reduction in oronasal airflow for >10 seconds, allocated to the CPAP treatment, and 41 subjects served
associated with an oxygen desaturation of ≥4%.23 The sever- as controls. In addition, 4 participants (all had no SCCEs)
ity of OSA was quantified numerically as the number of the withdrew before the end of study, 2 patients in the CPAP
AHI. AHI was defined as the total number of apneas and group withdrew before the 1-month visit (because of intoler-
hypopneas occurring per hour of sleep. Subjective daytime ance of CPAP treatment), and 2 patients in the control group
somnolence was assessed with the ESS questionnaire. A total withdrew before the 6-month visit (owing to live far from
score >10 was considered indicative of excessive daytime Beijing, complained of inconvenience). Two subjects were
sleepiness. lost to follow-up in the control group, and 4 patients (all
had no SCCEs) with very poor CPAP compliance were also
excluded. One participant in the control group died from
CPAP application
AMI before the 36-month visit and was included in the study
analysis. Thirty-six patients in the CPAP group and 37 sub- The CPAP group received fixed-level CPAP titration using
jects in the control group completed the study. The median
an automated pressure setting device for 1 night. The optimal
duration of follow-up was 36 (interquartile range = 24–54)
CPAP pressure for each patient in the CPAP group was set at
months.
the minimum pressure required to abolish snoring, obstruc-
tive respiratory events, and airflow limitation for 95% of the
night, according to a previous validation by our study.24 The Demographic and clinical data at baseline
fixed pressure was then maintained throughout the study in
patients who used a CPAP machine. CPAP compliance and Baseline characteristics and BP measurements were
AHI were objectively measured by the built-in compliance similar between the groups (Table 1). The mean age was
software of CPAP devices from the regular examination at 62.4 ± 6.7 years. Most subjects (82.2%) in this study were
the time of follow-up. Patients are generally considered ade- male and overweight (79.4% had BMI >25). Of all the
quately adherent to their CPAP treatment if the mean CPAP included patients, 36.8% had severe OSA, and 28 partici-
use was at least 4 hours/night. Each patient received stand- pants (38.4%) had daytime somnolence. Comorbidities were
ardized instructions by 1 investigator specialized in OSA similar between the CPAP treatment and the control groups.
and by a home healthcare provider at the start of the CPAP There were no significant differences with respect to drug
treatment. A specialist OSA team assisted patients with tel- number and category used by the patients between the 2
ephone or outpatient advice for any difficulties with CPAP groups. The SBPs in the CPAP treatment and control groups
during the study, and masks were adjusted as necessary. were 148 ± 11 mm Hg and 146 ± 8 mm Hg, respectively
(P = 0.41), and the DBPs in the 2 groups were 83 ± 8 mm Hg
and 83 ± 7 mm Hg, respectively (P = 0.85).
Statistical analysis
Continuous variables with normal distribution are Changes of clinical characteristics at follow-up
expressed as mean ± SD, and continuous variables without
normal distribution were expressed as median (interquartile The data from the follow-up are summarized in Table 2.
range), whereas categorical variables are reported as absolute The duration of follow-up did not differ significantly between
numbers and percentages. The sample size was calculated to the CPAP and control groups. Thirty-nine patients (57.4%)
assess a minimum reduction of 5 ± 5 mm Hg in systolic BP were followed for >36 months, and the shortest duration
American Journal of Hypertension 3
Downloaded
from
http://ajh.oxfordjournals.org/
at
University
of
California,
Santa
Cruz
on
February
11,
2015
Huang et al.
Figure 1. Flow diagram of the study. Abbreviations: CHD, coronary heart disease; CPAP, continuous positive airway pressure; OSA, obstructive sleep apnea.
was 18 months. There was no significant difference in BMI DiSCUSSiON
between the groups. In the CPAP group, AHI decreased from
To the best of our knowledge, this is the longest rand-
28.3 ± 13.0 events/hour (baseline) to 2.8 ± 1.4 events/hour (as
omized controlled trial specifically designed to investigate
estimated by the CPAP machine’s software). The AHI in the
the effects of CPAP treatment on BP and prognosis in hyper-
control group did not change significantly. Compared with
tensive patients with CHD and OSA. Our study demon-
the control group, ESS score was markedly reduced in the
strated that long-term CPAP therapy significantly reduced
therapeutic CPAP group (7.0 ± 3.4 vs. 3.7 ± 2.3; P < 0.001).
daytime SBP and improved hypertension control but did not
Smoking, diabetes mellitus, heart rate, neck circumference,
further decrease daytime DBP in hypertensive patients with
and number of drug treatment were not significantly dif-
CHD and OSA on conventional antihypertensive treatment.
ferent in the CPAP and control groups. The mean time of
There was a decreased trend in SCCEs in the CPAP group. CPAP treatment used by patients was 4.5 ± 1.1 hour/night.
Symptoms of daytime somnolence associated with OSA in
DBP at follow-up was lower but did not reach statistical dif-
the CPAP group were significantly improved compared with
ference between the groups (81 ± 10 mm Hg for controls vs.
controls.
79 ± 8 mm Hg for CPAP users, P = 0.49; ∆: 3 ± 11 mm Hg vs.
Previous studies have addressed the effects of CPAP on
4 ± 11 mm Hg, P = 0.75) (Figure 2). However, SBP was sig-
daytime BP in OSA patients. However, many of these tri-
nificantly different at the follow-up visit between the groups
als did not specifically investigate the effects of CPAP on
(143 ± 7 mm Hg for controls vs. 139 ± 7 mm Hg for CPAP
hypertensive patients, but instead were mainly targeted at
users, P = 0.043; ∆: 3 ± 6 mm Hg vs. 8 ± 11 mm Hg, P = 0.01)
normotensive subjects.25–27 Our study is different from these
(Figure 2). The proportion of controlled hypertension in the
studies in that the enrolled subjects were all hypertensive
CPAP group was better than in the control group at the end
patients with CHD and OSA. Both groups received conven-
of the study (P = 0.024). The number of antihypertensive
tional antihypertensive treatment during the course of study.
drugs was not significantly different at the time of follow-
Furthermore, a median long-term follow-up period of 36
up between the 2 groups. Three patients in the CPAP group
(interquartile range = 24–54) months is sufficient to detect
reported that nocturia significantly decreased. The CPAP
changes in BP.
group had an SCCE rate of 2.8% (n = 1/36; hospitalization
Several studies have analyzed the long-term effects of
for heart failure = 1), and the control group had an SCCE
CPAP on BP but have resulted in variable and conflicting
rate of 13.5% (n = 5/37; AMI = 2 (1 died from AMI before
outcomes. Campos-Rodriguez et al.28 showed that CPAP
the 36-month visit), stroke = 3). Although there was no dif-
treatment did not reduce BP in 68 OSA patients with hyper-
ference identified, there was a trend toward a lower percent-
tension over a period of 4 weeks. The results are different
age of SCCEs in the CPAP group.
from our study. The reasons for this are unclear but may
4 American Journal of Hypertension
Downloaded
from
http://ajh.oxfordjournals.org/
at
University
of
California,
Santa
Cruz
on
February
11,
2015
Effects of CPAP on Hypertensive Patients with OSA
Table 1. Baseline characteristics of patients in the continuous Table 2. Comparison of follow-up characteristics of patients
positive airway pressure and control groups between the control and continuous positive airway pressure
groups
Control CPAP
Variable (n = 37) (n = 36) P value Control CPAP
Variable (n = 37) (n = 36) P value
Age, y 62.7 ± 6.7 62.0 ± 6.8 0.68
Follow-up time, mo 36 (24–54) 36 (18–54) 0.85
Male sex 32 (86.5) 28 (77.8) 0.33
SCCEs 5 (13.5) 1 (2.8) 0.20
BMI, kg/m2 27.5 ± 2.6 27.9 ± 3.6 0.58
BMI, kg/m2 27.6 ± 2.6 28.0 ± 3.6 0.57
Smokers 23 (62.2) 19 (52.8) 0.42
Smokers 12 (32.4) 8 (22.2) 0.33
Diabetes mellitus 14 (37.8) 12 (33.3) 0.69
Diabetes mellitus 18 (48.6) 15 (41.7) 0.55
Myocardial infarction 14 (37.8) 11 (30.6) 0.51
Neck circumference, cm 40.5 ± 2.4 41.2 ± 4.3 0.41
Neck circumference, cm 40.9 ± 2.0 41.2 ± 4.0 0.65
Heart rate, bpm 65.0 ± 8.4 64.1 ± 7.0 0.64
Heart rate, bpm 64.0 ± 5.7 67.1 ± 9.7 0.10
ESS, points 7.0 ± 3.4 3.7 ± 2.3 <0.001
AHI, events/h 28.7 ± 12.4 28.3 ± 13.0 0.89
SBP, mm Hg 143 ± 7 139 ± 7 0.04
ESS, points 8.3 ± 3.4 9.3 ± 3.1 0.20
DBP, mm Hg 81 ± 10 79 ± 8 0.49
Minimum SaO, % 79.0 ± 4.7 78.9 ± 4.1 0.93
2
SBP change, mm Hg 3 ± 6 8 ± 11 0.01
SBP, mm Hg 146 ± 8 148 ± 11 0.41
DBP change, mm Hg 3 ± 11 4 ± 11 0.75
DBP, mm Hg 83 ± 7 83 ± 8 0.85
Beta-blocker 28 (75.7) 26 (72.2) 0.74
Beta-blocker 29 (78.4) 27 (75.0) 0.73
CCB 16 (43.2) 17 (47.2) 0.73
CCB 19 (51.4) 17 (47.2) 0.72
ACEI 15 (40.5) 12 (33.3) 0.52
ACEI 15 (40.5) 13 (36.1) 0.70
ARB 16 (43.2) 14 (38.9) 0.71
ARB 13 (35.1) 11 (30.6) 0.68
Diuretics 27 (73.0) 22 (61.1) 0.28
Diuretics 19 (51.4) 21 (58.3) 0.55
Drug change 19 (48.6) 15 (41.7) 0.55
Antihypertensive drugs 3.2 ± 0.4 3.3 ± 0.6 0.82
Antihypertensive drugs 3.6 ± 0.5 3.3 ± 0.4 0.053
Values are mean ± SD or No. (%).
Hypertension control 16 (43.2) 25 (69.4) 0.02
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor;
AHI, apnea–hypopnea index; ARB, angiotensin receptor blocker;
Values are mean ± SD, median (interquartile range), or No. (%).
BMI, body mass index; bpm, beats per minute; CCB, calcium chan-
Change is defined as baseline minus follow-up value.
nel blocker; CPAP, continuous positive airway pressure; DBP, dias-
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor;
tolic blood pressure; ESS, Epworth Sleepiness Scale; SBP, systolic
ARB, angiotensin receptor blocker; CCB, calcium channel blocker;
blood pressure.
CPAP, continuous positive airway pressure; DBP, diastolic blood
pressure; ESS, Epworth Sleepiness Scale; SBP, systolic blood pres-
sure; SCCEs, severe cardiovascular and cerebrovascular events.
relate to the fact that the BMI in their study was significantly
higher than in ours (75% of patients had obesity; mean
BMI = 35.9 kg/m2 vs. 27.7 kg/m2). Obesity is an independent levels or a need for less antihypertensive drugs for BP control
risk factor, may contribute to worsening of BP control, and is in nonsleepy, hypertensive, OSA patients on conventional
not affected by CPAP. Moreover, the study duration was only antihypertensive treatment. The outcomes are different from
4 weeks. Barbé et al.9 conducted a multicenter, randomized ours. However, the study has some obvious limitations. The
controlled trial with the largest sample, which confirmed a subjects in their study had a significant difference in severity
small reduction in BP. The different results may have been of OSA at baseline (P = 0.005), and the rate of diuretics use in
caused by the fact that subjects were all nonsleepy hyper- the study was only 36.3%. Furthermore, the study included
tensive patients. In contrast, 38.4% participants in our study patients who had no subjective complaints of sleepiness. The
had daytime somnolence. Robinson et al.29 reported that the clinical significance of this is unknown.
fall in ESS score was an independent predictor of a fall in Our outcomes suggest that CPAP was effective in lower-
24-hour ambulatory BP, but baseline severity of OSA, over- ing SBP in uncontrolled hypertensive patients with CHD
night hypoxia, caffeine intake, and being on antihypertensive and OSA and are consistent with the following trials. A few
drugs were not independent predictors of a fall in 24-hour nonrandomized studies have consistently indicated that
ambulatory BP. We found that ESS score in the CPAP CPAP treatment in OSA patients with resistant hyper-
group was significantly reduced from 9.3 ± 3.1 at baseline to tension mainly resulted in reductions in SBP (from 5.2 to
3.7 ± 2.3 at the time of follow-up. The change in SBP in the 2 11 mm Hg).31–33 International guidelines have pointed out
groups between baseline and post-treatment was remarkable that even minimal reductions in the SBP (2–3 mm Hg) in
(∆:2.5 mm Hg for controls vs. 8.3 mm Hg for CPAP users; the older population could have a clinically significant effect
P = 0.01). One study from Kasiakogias et al.30 suggested that by greatly reducing subsequent cardiovascular mortality
long-term CPAP application is not associated with lower BP (between 6%–8% for stroke and 4%–5% for coronary heart
American Journal of Hypertension 5
Downloaded
from
http://ajh.oxfordjournals.org/
at
University
of
California,
Santa
Cruz
on
February
11,
2015
Huang et al.
Figure 2. Comparison of blood pressure at baseline and follow-up between the continuous positive airway pressure (CPAP)–treated and control
groups. Abbreviations: DBP, diastolic blood pressure; SBP, systolic blood pressure. ★ P < 0.05.
disease).22 Untreated OSA is strongly associated with poor In conclusion, this study confirmed that long-term appli-
BP control, particularly severe OSA. A review study clearly cation of CPAP in uncontrolled hypertensive patients with
demonstrates that untreated OSA is associated with greater CHD and OSA receiving standardized treatment signifi-
difficulty in the control of hypertension.34 This notion sup- cantly reduced daytime SBP, improved hypertension con-
ports our finding that the rate of hypertension control in the trol and daytime sleepiness, and led to a decreased trend in
control group is poorer than in the CPAP-treated group. SCCEs compared with control subjects. A practical clinical
Additionally, compared with control subjects, only 1 message from our study is that it would be wise and rec-
patient presented with an SCCE in the CPAP group,but 5 ommended to apply CPAP in uncontrolled hypertensive
subjects had SCCEs in the control group. Of the 5 subjects, patients with moderate to severe OSA being treated with
1 died from AMI. The data are encouraging, although there conventional BP medication. In the future, larger samples
was no difference identified. We believe that a longer follow- studies are necessary to clarify the impact of CPAP on prog-
up period and larger sample size may have resulted in a sta- nosis in hypertensive patients with CHD and OSA.
tistical difference. If the speculation is confirmed, it is very
meaningful to the population with OSA and CHD. Boden-
Albala and colleagues have shown that daytime sleepiness
is an independent risk factor for stroke and other vascu-
ACKNOwLEDgMENTS
lar events.35 This may explain why the control group had a
higher incidence of stroke than the CPAP group. We thank Baoyu Feng for her contribution to the sta-
Nevertheless, our study has some limitations. First, the tistical analysis. This work was supported by the Research
sample size was relatively small. However, we performed a Fund of Capital Medical Development of Beijing Municipal
long-term follow-up to determine the real effects of CPAP Health Bureau (No. 2009–2012).
on BP in the specific population. Second, this was a non-
double-blind study. However, the use of sham CPAP in the
DiSCLOSURE
long-term study is impractical. Given this situation, the
investigator responsible for BP measurements and clinical
The authors declared no conflict of interest.
assessments was blind to the allocation of CPAP. It is useful
to avoid observer bias. Third, we did not use 24-hour ambu-
latory BP to monitor changes in BP and could not evaluate
the nighttime BP. However, 24-hour ambulatory BP may
have a cuff pressure effect and cause arousal in sleeping sub- REFERENCES
jects, thereby increasing the SBP and DBP. Also, most of our
1. Shamsuzzaman AS, Gersh BJ, Somers VK. Obstructive sleep
enrolled subjects were men. Further studies are required to
apnea: implications for cardiac and vascular disease. JAMA 2003;
extrapolate the results to the female population. 290:1906–1914.
6 American Journal of Hypertension
Downloaded
from
http://ajh.oxfordjournals.org/
at
University
of
California,
Santa
Cruz
on
February
11,
2015
Effects of CPAP on Hypertensive Patients with OSA
2. Kiely JL, McNicholas WT. Cardiovascular risk factors in patients with 19. Campos-Rodriguez F, Martinez-Garcia MA, de la Cruz-Moron I,
obstructive sleep apnoea syndrome. Eur Respir J 2000; 16:128–133. Almeida-Gonzalez C, Catalan-Serra P, Montserrat JM. Cardiovascular
3. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the asso- mortality in women with obstructive sleep apnea with or without con-
ciation between sleep-disordered breathing and hypertension. N Engl J tinuous positive airway pressure treatment: a cohort study. Ann Intern
Med 2000; 342: 1378–1384. Med 2012; 156:115–122.
4. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White 20. Sleep-related breathing disorders in adults: recommendations for syn-
A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner drome definition and measurement techniques in clinical research. The
B, Carey RM. Resistant hypertension: diagnosis, evaluation, and treat- report of an American Academy of Sleep Medicine Task Force. Sleep
ment: a scientific statement from the American Heart Association 1999; 22:667–689.
Professional Education Committee of the Council for High Blood 21. Johns MW. A new method for measuring daytime sleepiness: the
Pressure Research. Circulation 2008; 117:e510–e526. Epworth Sleepiness Scale. Sleep 1991; 14:540–545.
5. Muxfeldt ES, Margallo VS, Guimarães GM, Salles GF. Prevalence and 22. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL
associated factors of obstructive sleep apnea in patients with resistant Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. The sev-
hypertension. Am J Hypertens 2014; e-pub ahead of print 14 April 2014. enth report of the Joint National Committee on Prevention, Detection,
6. Mooe T, Rabben T, Wiklund U, Franklin KA, Eriksson P. Sleep- Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
disordered breathing in men with coronary artery disease. Chest 1996; JAMA 2003; 289:2560–2572.
109:659–663. 23. Martínez-García MA, Capote F, Campos-Rodríguez F, Lloberes P, Díaz
7. Peker Y, Hedner J, Kraiczi H, Löth S. Respiratory disturbance index: de Atauri MJ, Somoza M, Masa JF, González M, Sacristán L, Barbé F,
an independent predictor of mortality in coronary artery disease. Am J Durán-Cantolla J, Aizpuru F, Mañas E, Barreiro B, Mosteiro M, Cebrián
Respir Crit Care Med 2000; 162:81–86. JJ, de la Peña M, García-Río F, Maimó A, Zapater J, Hernández C, Grau
8. Campos-Rodriguez F, Perez-Ronchel J, Grilo-Reina A, Lima-Alvarez SanMarti N, Montserrat JM. Effect of CPAP on blood pressure in
J, Benitez MA, Almeida-Gonzalez C. Long-term effect of continuous patients with obstructive sleep apnea and resistant hypertension: the
positive airway pressure on BP in patients with hypertension and sleep HIPARCO randomized clinical trial. JAMA 2013; 310:2407–2415.
apnea. Chest 2007; 132:1847–1852. 24. Zhao Q, Liu ZH, Luo Q, Zhao ZH, Zhang HL, Wang Y. Effects of con-
9. Barbé F, Durán-Cantolla J, Capote F, de la Peña M, Chiner E, Masa JF, tinuous positive airway pressure on blood pressure and daytime sleepi-
Gonzalez M, Marín JM, Garcia-Rio F, de Atauri JD, Terán J, Mayos M, ness in obstructive sleep apnea patients with coronary heart diseases
Monasterio C, del Campo F, Gomez S, de la Torre MS, Martinez M, under optimal medications. Sleep Breath 2012; 16:341–347.
Montserrat JM. Long-term effect of continuous positive airway pres- 25. Dimsdale JE, Loredo JS, Profant J. Effect of continuous positive air-
sure in hypertensive patients with sleep apnea. Am J Respir Crit Care way pressure on blood pressure: a placebo trial. Hypertension 2000;
Med 2010; 181:718–726. 35:144–147.
10. Montesi SB, Edwards BA, Malhotra A, Bakker JP. The effect of continu- 26. Faccenda JF, Mackay TW, Boon NA, Douglas NJ. Randomized placebo-
ous positive airway pressure treatment on blood pressure: a systematic controlled trial of continuous positive airway pressure on blood pres-
review and meta-analysis of randomized controlled trials. J Clin Sleep sure in the sleep apnea-hypopnea syndrome. Am J Respir Crit Care Med
Med 2012; 8:587–596. 2001; 163:344–348.
11. Becker HF, Jerrentrup A, Ploch T, Grote L, Penzel T, Sullivan CE, Peter 27. Pepperell JC, Ramdassingh-Dow S, Crosthwaite N, Mullins R,
JH. Effect of nasal continuous positive airway pressure treatment on Jenkinson C, Stradling JR, Davies RJ. Ambulatory blood pressure after
blood pressure in patients with obstructive sleep apnea. Circulation therapeutic and subtherapeutic nasal continuous positive airway pres-
2003; 107:68–73. sure for obstructive sleep apnoea: a randomised parallel trial. Lancet
12. Sanner BM, Tepel M, Markmann A, Zidek W. Effect of continuous posi- 2002; 359:204–210.
tive airway pressure therapy on 24-hour blood pressure in patients with 28. Campos-Rodriguez F, Grilo-Reina A, Perez-Ronchel J, Merino-Sanchez
obstructive sleep apnea syndrome. Am J Hypertens 2002; 15:251–257. M, Gonzalez-Benitez MA, Beltran-Robles M, Almeida-Gonzalez C.
13. Börgel J, Sanner BM, Keskin F, Bittlinsky A, Bartels NK, Büchner N, Effect of continuous positive airway pressure on ambulatory BP in
Huesing A, Rump LC, Mügge A. Obstructive sleep apnea and blood patients with sleep apnea and hypertension: a placebo-controlled trial.
pressure. Interaction between the blood pressure-lowering effects of Chest 2006; 129:1459–1467.
positive airway pressure therapy and antihypertensive drugs. Am J 29. Robinson GV, Langford BA, Smith DM, Stradling JR. Predictors of
Hypertens 2004; 17:1081–1087. blood pressure fall with continuous positive airway pressure (CPAP)
14. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascu- treatment of obstructive sleep apnoea (OSA).Thorax 2008;63:855–859.
lar outcomes in men with obstructive sleep apnoea-hypopnoea with or 30. Kasiakogias A, Tsioufis C, Thomopoulos C, Aragiannis D, Alchanatis
without treatment with continuous positive airway pressure: an obser- M, Tousoulis D, Papademetriou V, Floras JS, Stefanadis C. Effects of
vational study. Lancet 2005; 365:1046–1053. continuous positive airway pressure on blood pressure in hypertensive
15. Doherty LS, Kiely JL, Swan V, McNicholas WT. Long-term effects of patients with obstructive sleep apnea: a 3-year follow-up. J Hypertens
nasal continuous positive airway pressure therapy on cardiovascular 2013;31:352–360.
outcomes in sleep apnea syndrome. Chest 2005; 127:2076–2084. 31. Logan AG, Tkacova R, Perlikowski SM, Leung RS, Tisler A, Floras JS,
16. Campos-Rodriguez F, Grilo-Reina A, Perez-Ronchel J, Merino-Sanchez Bradley TD. Refractory hypertension and sleep apnoea: effect of CPAP
M, Gonzalez-Benitez MA, Beltran-Robles M, Almeida-Gonzalez C. on blood pressure and baroreflex. Eur Respir J 2003; 21:241–247.
Effect of continuous positive airway pressure on ambulatory BP in 32. Martínez-García MA, Gómez-Aldaraví R, Soler-Cataluña JJ, Martínez
patients with sleep apnea and hypertension: a placebo-controlled trial. TG, Bernácer-Alpera B, Román-Sánchez P. Positive effect of CPAP
Chest 2006; 129:1459–1467. treatment on the control of difficult-to-treat hypertension. Eur Respir
17. Barbé F, Mayoralas LR, Duran J, Masa JF, Maimó A, Montserrat JM, J 2007; 29:951–957.
Monasterio C, Bosch M, Ladaria A, Rubio M, Rubio R, Medinas M, 33. Dernaika TA, Kinasewitz GT, Tawk MM. Effects of nocturnal continu-
Hernandez L, Vidal S, Douglas NJ, Agustí AG. Treatment with continu- ous positive airway pressure therapy in patients with resistant hyper-
ous positive airway pressure is not effective in patients with sleep apnea tension and obstructive sleep apnea. J Clin Sleep Med 2009; 5:103–107.
but no daytime sleepiness. a randomized, controlled trial. Ann Intern 34. Dudenbostel T, Calhoun DA. Resistant hypertension, obstructive sleep
Med 2001; 134:1015–1023. apnoea and aldosterone. J Hum Hypertens 2012; 26:281–287.
18. Cassar A, Morgenthaler TI, Lennon RJ, Rihal CS, Lerman A. Treatment 35. Boden-Albala B, Roberts ET, Bazil C, Moon Y, Elkind MS, Rundek T,
of obstructive sleep apnea is associated with decreased cardiac death Paik MC, Sacco RL. Daytime sleepiness and risk of stroke and vascular
after percutaneous coronary intervention. J Am Coll Cardiol 2007; disease: findings from the Northern Manhattan Study (NOMAS). Circ
50:1310–1314. Cardiovasc Qual Outcomes 2012; 5:500–507.
American Journal of Hypertension 7
Downloaded
from
http://ajh.oxfordjournals.org/
at
University
of
California,
Santa
Cruz
on
February
11,
2015
